Introduction c-Jun is an important component of transcription factor activator protein-1 (AP-1), and is activated by a variety of stress stimuli and plays the pivotal role in cellular responses including cell growth, apoptosis, differentiation, and gene expression. 1 Previously, we constructed dominant-negative c-Jun (DN-c-Jun) as the tool to specifically inhibit c-Jun and examined the effect of DN-c-Jun gene transfer on balloon-injured rat carotid artery in vitro 2 or cultured vascular smooth muscle cells in vitro. 3 We found that blockade of c-Jun by gene transfer of DN-c-Jun inhibited vascular smooth muscle cell proliferation and migration in vivo or in vitro, thereby proposing that suppression of c-Jun is useful for treatment of vascular hyperplasia.
2,3 Furthermore, we have determined the activities of cardiac AP-1 in angiotensin II (AngII)-infused rats 4 and stroke-prone spontaneously hypertensive rats (SHRSP). 5 We have found that cardiac AP-1 activity, related to c-Jun, is activated in AngII-infused rats and SHRSP. However, the significance of c-Jun for cardiac diseases remains to be defined, mainly because of the lack of the specific and potent pharmacological inhibitor of c-Jun. In the present study, to define the contribution of c-Jun to cardiac hypertrophy and gene expression induced by AngII or hypertension, we carried out cardiac transfer of adenoviral vector containing DN-c-Jun (Ad.DN-c-Jun) in vivo. We obtained the evidence that c-Jun is a potent therapeutic target for cardiac disease.
Methods

Animals and experimental design
All procedures were in accordance with institutional guidelines for the care and use of laboratory animals. All rats were fed a standard laboratory chow (CE-2, Clea Japan) and given tap water ad libitum. In the first experiment, 9-week-old male Sprague-Dawley rats (Clea Japan) were used. At 2 days after rats received the transfer of Ad.DN-c-Jun or adenovirus containing bacterial b-galactosidase gene (AD.LacZ) as described later, AngII (200 ng/kg/min) was subcutaneously infused to rats via osmotic minipump, as described by us, 6 to examine the effect of DN-c-Jun gene transfer on AngII-induced hypertension, cardiac hypertrophy, and gene expressions. In the second experiments, 8-week-old male SHRSP (SLC Japan) were used as the model of hypertensive cardiac hypertrophy. SHRSP were subjected to cardiac transfer of Ad.DN-c-Jun or Ad.LacZ as described later, to examine the effect of DN-c-Jun on hypertensive cardiac hypertrophy.
Construction of recombinant adenovirus containing DN-c-Jun
The dominant-negative mutant of c-Jun, called TAM67, was generated by removal of the transactivational domain of amino acids 3-122 of wild-type c-Jun by polymerase chain reaction, as described. 2, 7 TAM67 has the DNA-binding domain of wild-type c-Jun. Recombinant replication-defective E1 and E3 adenoviral vectors expressing the TAM67 gene (Ad.DN-c-Jun) were constructed by using an adenovirus expression vector kit (Takara Biomedicals), according to the method of Miyake et al. 8 cDNA encoding TAM67 was placed into a cassette cosmid vector, PaxCAwt, which possesses the CAG promoter, composed of a cytomegalovirus enhancer, chicken b-actin promoter, and rabbit a-globin poly(A) signal. A recombinant adenovirus was constructed by in vitro homologous recombination in 293 cells by using the above cosmid vector, PaxCAwt, containing TAM67 cDNA and the adenovirus DNA-terminal protein complex. Ad.LacZ was also constructed as the negative control of Ad.DN-c-Jun, in the same way as Ad.DN-cJun. All the adenoviral vectors were purified with CsCl gradient centrifugation, dialyzed with a buffer containing 10 mM Tris (pH 7.5), 1 mM MgCl 2 and 10% glycerol, and stored in aliquots at À701C. 9 The titer of the virus was determined by plaque assay and expressed as PFU/ml.
Adenoviral delivery protocol
Cardiac adenoviral delivery was performed according to the method of Hajjar et al. 10 Rats were anesthetized with sodium pentobarbital i.p. and placed on a ventilator. The chest was entered from the left side through the third intercostal space. The pericardium was opened and the aorta was identified. A 24G catheter containing 200 ml of adenovirus containing approximately 10 10 plaqueforming units of either Ad.LacZ or Ad.DN-c-Jun was advanced from the apex of the left ventricle to the aortic root. The aorta was clamped distal to the site of the catheter and the solution injected. The clamp was maintained for 10 s. This procedure allows the solution that contains the adenovirus to circulate down the coronary arteries and perfuse the heart without direct manipulation of the coronaries. After 10 s, the clamp on the aorta was released. After removal of air and blood, the chest was closed, and animals were extubated and transferred back to their cages.
In the preliminary experiments, by Western blot analysis, we compared the expression of b-galactosidase in cardiac tissue at 1, 2, 5, and 7 days after cardiac transfer of Ad.LacZ to determine when the maximal protein expression is achieved in cardiac tissue. We found that the maximal b-galactosidase expression occurred at 2 days after the cardiac gene transfer. Therefore, we carried out cardiac gene transfer of Ad.LacZ or Ad.DN-c-Jun, 2 days before AngII infusion.
Western blot analysis
Protein extracts from LV were separated on a 12% SDSpolyacrylamide gel and immobilized on polyvinylidene difluoride membrane, as described in detail by us. 2 The membrane was immunoblotted with anti-c-Jun antibody (sc-44; Santa cruz), anti-b-galactosidase, anti-phosphop70S6 kinase (Promega), anti-p70S6 kinase (Promega), and anti-a-tubulin, using the enzyme-linked chemiluminescence (ECL) method as described previously. 2 RNA preparation and Northern blot analysis. All procedures were performed, as described in detail in our previous reports. 6, 11 In brief, 20 mg of total RNA samples from individual left ventricle were subjected to 1% agarose gel electrophoresis, transferred onto nylon membrane, and hybridization was carried out with ( 32 P)dCTP-labeled cDNA probe for collagen type I, collagen type III, collagen type IV, monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and ( 32 p)ATP-labeled oligonucleotides complimentary to a-myosin heavy chain (a-MHC), and b-myosin heavy chain (b-MHC). 6, 11 The densities of an individual mRNA band were measured by using a bioimaging analyzer (BAS-2000, Fuji Photo film Co., Tokyo, Japan).
Gel mobility shift assays
For DNA protein-binding reaction, gel mobility assays were performed as described in detail by us. [2] [3] [4] The sequence of double-strand consensus oligonucleotides of AP-1, NF-kB, Sp-1, and CREB were previously described. Supershift assay was performed with rabbit polyclonal anti-c-Fos IgG (sc-253-G, 2 mg), anti-c-Jun IgG (sc-822X, 2 mg) recognizing the amino acids from 56 to 69 (transactivation domain) of wild c-Jun, or anti-c-Jun IgG (sc-44X, 2 mg) recognizing the conserved DNAbinding domain of wild c-Jun (all from Santa Cruz).
Histochemistry
To evaluate the expression of b-galactosidase in the heart subjected to Ad.LacZ gene transfer, hearts were fixed with PBS containing 0.5% glutaraldehyde for 30 min and then in PBS with 30% sucrose for 30 min. The hearts were then permeabilized by incubation in solution containing sodium deoxycholate (0.01%) and Nonidet P-40 for 15 min. Then the hearts were incubated overnight in a solution containing 5-bromo-4-chloro3-indolyl-D-galactopyranoside (X-Gal), and 10-mm sections were then cut and examined under light microscopy.
To examine the expression of DN-c-Jun in the heart subjected to Ad.DN-c-Jun gene transfer, the heart was fixed with 4% paraformaldehyde and frozen in OCTcompound and the frozen sections were immunostained with the above-mentioned anti-c-Jun IgG (sc-822X) recognizing the transactivation domain of c-Jun, or anti-c-Jun IgG (sc-44X) recognizing the conserved DNA-binding domain of c-Jun, and then diaminobenzidine.
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Statistical significance was determined by one-way ANOVA followed by Duncan's multiple range test. Differences were considered statistically significant at a value of Po0.05. Gel mobility shift analysis of left ventricular nuclear protein from rats subjected to gene transfer of LacZ or DN-c-Jun
Results
Cardiac
Previously, we confirmed that Ad.DN-c-Jun employed in our work specifically inhibited transcriptional activity of AP-1, using luciferase assay. 2, 3 As shown by gel mobility shift analysis in Figure 3 , Ad.DN-c-Jun gene transfer increased AP-1 DNA-binding activity. However, the position of AP-1 band due to Ad.DN-c-Jun was upper to that of endogenous AP-1, being in good agreement with our previous papers. 2, 3, 12, 13 As shown by supershift analysis, endogenous AP-1 band was supershifted with Effects of DN-c-Jun gene transfer on angiotensin II-induced hypertension, and cardiac hypertrophy, p70S6 kinase and gene expressions
As shown in Figure 4 (a), blood pressure of rats was significantly increased at 3 and 7 days after start of AngII infusion, compared with control rats subjected to saline infusion. No significant difference in blood pressure was noted between two groups of rats subjected to gene transfer of LacZ and DN-c-Jun, throughout AngII infusion.
There was no significant difference in body weight among these three groups of rats at the end of the experiments. AngII infusion for 7 days increased LV weight compared with control (2.5270.05 vs 1.9470.05 mg/g BW, Po0.01), and this increase in LV weight was significantly suppressed by DN-c-Jun gene transfer (2.2170.05 mg/g BW, Po0.01 (Figure 4(b) ). LV phospho-p70S6 kinase levels were increased by AngII infusion by 1.3-fold (Po0.05) and DNc-Jun gene transfer significantly inhibited AngII-induced activation of LV p70S6 kinase (Po0.01 (Figure 4(c) ). Figure 5 shows the effect of DN-c-Jun gene transfer on LV mRNA expressions related to cardiac hypertrophy and remodeling. LV mRNA levels for collagen I, III and IV, MCP-1, PAI-1 and BNP were elevated by AngII infusion by 1.6-, 1.5-, 1.5-, 1.8-, 2.4-, and 1.6-fold, respectively, and DNc-Jun gene transfer significantly reduced all these mRNA levels. On the other hand, DN-c-Jun failed to suppress LV ANP mRNA expression, which were increased by AngII infusion by 5.4-fold. Interestingly, LV a-MHC mRNA expression, which was not altered by AngII infusion, was increased by DN-c-Jun gene transfer by 1.6-fold (Po0.05).
Effects of DN-c-Jun gene transfer on blood pressure, and cardiac hypertrophy, p70S6kinase and gene expressions of hypertensive rats
As shown in Figure 6 (a), there was no difference in blood pressure between LacZ group and DN-c-Jun group of SHRSP before cardiac gene transfer (16272 vs 16372 mmHg). DN-c-Jun transfer did not significantly affect blood pressure of SHRSP compared with control SHRSP at 7 and 14 days (17772 vs 17771 mmHg). LV weight corrected for body weight in DN-c-Jun group was smaller than that in control group (2.87670.034 vs 3.04470.052 mg/g BW, Po0.05) (Figure 6(b) ). LV phospho-p70S6 kinase levels in DN-c-Jun group was lower than those in control group (Po0.05) (Figure 6(c) ). Cardiac echocardiography in Figure 7 Previous reports on in vivo experiments, by us and other groups of investigators, have showed that AngII is importantly involved in cardiac hypertrophy and remodeling, independently of blood pressure. 6, 11, 14, 15 Moreover, AngII in vivo and in vitro induces the activation of Co III Figure 5 Effect of DN-c-Jun gene transfer on LV mRNA levels related to cardiac hypertrophy and remodeling in AngII-infused rats. Individual mRNA levels were corrected for GAPDH mRNA levels. Values are means7s.e.m. (n ¼ 7 in each group). The mean value in control group (saline infusion) is expressed as 1.
In vivo blockade of c-Jun in cardiac hypertrophy S Kim-Mitsuyama et al AP-1 related to c-Jun in cardiomyocytes. 4 However, the molecular mechanism responsible for AngII-induced cardiac hypertrophy in vivo remains to be determined. There is no available report on the effect of c-Jun inhibition on cardiac hypertrophy in vivo, which encouraged us to examine the possible role of c-Jun in AngIIinduced cardiac disease. To specifically inhibit cardiac c-Jun in vivo, we used gene transfer technique with adenoviral vector. The abundant expression of transferred gene in cardiac tissue by our technique, as shown in Figures 1-3 , demonstrated the successful gene transfer technique employed in our work.
In the present experiments, we found that DN-c-Jun gene transfer significantly suppressed AngII-induced cardiac hypertrophy and gene expressions, despite no effect on blood pressure. These results demonstrate that c-Jun plays a critical role in AngII-induced cardiac disease. The suppression of cardiac hypertrophy by gene transfer of DN-c-Jun was accompanied by the inhibition of p70S6 kinase phosphorylation. p70S6 kinase is a physiological kinase for the 40S ribosomal S6 protein and plays the critical role in protein synthesis. 16 Furthermore, p70S6 kinase phosphorylation is involved in AngIIor phenylephrine-induced cardiomyocyte hypertrophy in vitro 17, 18 and is significantly activated in hypertensive heart. 19 Taken together with these findings, our observation suggests that p70S6 kinase may play some role in the prevention of AngII-induced cardiac hypertrophy by c-Jun blockade. However, further study is needed to elucidate our proposal.
In this study, AngII infusion caused the upregulation of cardiac mRNAs for collagen I, III and IV, ANP, BNP, MCP-1 and PAI-1, being in good agreement with our previous reports. 6 Of note are the observations that c-Jun blockade led to the inhibition of upregulation of the above-mentioned gene expressions except for ANP. Furthermore, c-Jun blockade caused the upregulation of a-MHC. These results demonstrated that c-Jun plays a pivotal role in AngII-mediated gene expression related to cardiac hypertrophy and remodeling.
To elucidate whether the important role of c-Jun in pathologic cardiac hypertrophy is limited to AngIImediated cardiac hypertrophy or not, we also investigated the effect of DN-c-Jun on cardiac hypertrophy in SHRSP. SHRSP is the most popular model of genetic hypertension and is the very useful model of hypertensive cardiac hypertrophy and remodeling. 11, 14, 15, 20 We have previously shown that SHRSP exhibits cardiac hypertrophy and upregulation of cardiac hypertrophyand remodeling-associated gene expression, compared with normotensive rats.
11,15 Moreover, we have reported that cardiac AP1 activity related to c-Jun is significantly increased in SHRSP compared with normotensive rats. 21 In this study, as in the case of AngII-infused rats as described above, cardiac gene transfer of DN-c-Jun in SHRSP regressed cardiac hypertrophy and reduced p70S6 kinase phosphorylation. Moreover, DN-c-Jun gene transfer suppressed the upregulation of cardiac collagen I, III and IV, MCP-1 and PAI-1 in SHRSP, being in -and actin-activated ATPase activity, is associated with an increased shortening velocity of the cardiac fibers, whereas b-MHC, which has lower ATPase activity, is associated with slower shortening velocity. 22, 23 Therefore, the alteration of ratio of a-MHC to b-MHC significantly affects cardiac performance. Collectively, our present results suggest that c-Jun may be implicated in the regulation of cardiac contractile protein, although further study is needed to elucidate our assumption.
In conclusion, our present experimental observations support the notion that c-Jun is implicated in pathologic cardiac hypertrophy and delivery of DN-c-Jun may have some utility for treatment of cardiac hypertrophy. However, the clinical application of DN-c-Jun is hampered by the short-lived nature of adenovirus expression and inherent problems with immune recognition and reaction. Therefore, the technical development of gene delivery to the heart is essential to elucidate the significance of DN-c-Jun delivery in cardiac disease. In vivo blockade of c-Jun in cardiac hypertrophy S Kim-Mitsuyama et al
